It is estimated that one third of the world's population is infected with , the causative agent of Tuberculosis (TB). The BCG vaccine is widely used to fight against TB; however, many question its ability to provide complete protection from . Recently, the "Region of Difference 1" (RD1) set of genes were shown to be involved in the pathogenesis of . Downstream of RD1 transcription region, two proteins are encoded, known as EspB and EspC, which were found to contribute to virulence.In this study these two proteins are targeted as potential vaccine candidates against TB.The EspB and EspC genes were codon-optimized for expression and synthesis in (E. coli). The amplicons were cloned into a pET21a expression vector and transformed into (DE3). The expression and purity of the expressed proteins (i.e. rEspC, rEspB and rEspC/EspB) were confirmed by SDS-PAGE and Western blotting. Moreover, BALB/c mice were immunized against using the recombinant proteins. Finally, the mice sera were analyzed via Western blotting.EspC, EspB, and EspC/EspB fusion genes were cloned and expressed in . Both SDS-PAGE and Western blots confirmed the presence and successful purification of the desired proteins. Moreover, antisera produced against the purified recombinant proteins reacted with proteins.rEspC, rEspB, and rEspC/EspB could be expressed and purified using an expression system. The recombinant proteins induced the production of antibodies in BALB/c mice that reacted with proteins.